## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Merck Sharp & Dohme Limited

Serial No.:

To Be Assigned

Case No.: T1600YP

US Nat'l Filing Date:

April 27, 2005

Int'l Appl'n No.

PCT/GB03/004707

Int'l Filing Date:

29 October 2003

For:

SULFONAMIDES, SULFAMATES AND SULFAMIDES AS

**GAMMA-SECRETASE INHIBITORS** 

MAIL STOP PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR § 1.97**

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

**EXPRESS MAIL CERTIFICATE** 

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY A QU

DATE



Int'l Appl'n I

PCT/GB03/004707

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A & B were listed in the International Search Report during the International phase of this application.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the non-U.S. patent documents that are cited on the attached form PTO-1449 are enclosed herewith.

All the references cited on the attached form were cited in the International Search Report for this application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

ohn C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: April 27, 2005

	JC20 Rec	Approved for use through 7/31/2006. OMB 0651-0031  Approv			
Substitute for form 1449A/PTO	COMPLETE CONTROL IN TO 15 77 1 F 4				
INFORMATION DISCLE RE	Application Number	PCT/GB03/			
STATEMENT BY APPLICANT	Filing Date	April 27, 2005			
	First Named Inventor	Andrew Madin et al.			
Anna manna at an	Group Art Unit	To Be Assigned			
(use as many sheets as necessary)	Examiner Name	To Be Assigned			

Attorney Docket Number

T1600YP

1

of

1

Sheet

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Office	Foreign Patent Documer  Number	K	ind ode nown)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A		WO 02/36555	]]	PCT	Merck Sharp & Dohme Limited	05/10/2002
	В		WO 01/70677	]	PCT	Merck Sharp & Dohme Limited and	
						Merck Frosst Canada & Co.	09/27/2001
						·	

Evaminar	Data	
Examiner	Date	
Cianotura	Canadanad	
Signature	Considered	
	00110100100	1

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., 09/05/2003